Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease

European Heart Journal

Volumn 20, Issue 22, 1999, Pages 1657-1666

  Oldgren, J ^a   Linder, R ^b   Grip, L ^c   Siegbahn, A ^a   Wallentin, L ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticoagulants; Myocardial infarction; Prognosis; Thrombosis; Unstable angina

Indexed keywords

HEPARIN; INOGATRAN; THROMBIN INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; UNSTABLE ANGINA PECTORIS;

EID: 0033230262     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1750     Document Type: Article

References (35)

1. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation. 77:1988;1213-1220.
2. Lewis HD Jr., Davis JW, Archibald DG. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 309:1983;396-403.
3. Cairns JA, Gent M, Singer J. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 313:1985;1369-1375.
4. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol. 18:1991;1587-1593.
5. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. 1:1981;1225-1228.
6. Théroux P, Ouimet H, McCans J. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 319:1988;1105-1111.
7. Théroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 88:1993;2045-2048.
8. Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 327:1992;141-145.
9. Lancet. 347:1996;561-568.
10. N Engl J Med. 335:1996;775-782.
11. Circulation. 96:1997;769-777.
12. Teger-Nilsson AC, Bylund R, Gustafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Thromb Res. 85:1997;133-145.
13. Gustafsson D, Elg M, Lenfors S, Borjesson I, Teger-Nilsson AC. Effects of inogatran, a new low-molecular-weight thrombin inhibitor. Blood Coagul Fibrinolysis. 7:1996;69-79.
14. Eur Heart J. 18:1997;1416-1425.
15. Moreno PR, Bernardi VH, López-Cuéllar J. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 94:1996;3090-3097.
16. Bain B, Forster T, Sleigh B. Heparin and the activated partial thromboplastin time - a difference between the in-vitro and in-vivo effects and implications for the therapeutic range. Am J Clin Pathol. 74:1980;668-673.
17. Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost. 70:1993;286-288.
18. Nurmohamed MT, Berckmans RJ, Morriën-Salomons WM. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays. Thromb Haemost. 72:1994;685-692.
19. Poller L, Thomson JM, Taberner DA. Use of the activated partial thromboplastin time for monitoring heparin therapy: problems and possible solutions. Res Clin Lab. 19:1989;363-370.
20. Shojania AM, Tetreault J, Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol. 89:1988;19-23.
21. Zoldhelyi P, Webster MW, Fuster V. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation. 88:1993;2015-2022.
22. Braunwald, E, Mark, DB, Jones, RH, Unstable angina: diagnosis and management.
23. Hirsh J. Heparin. N Engl J Med. 324:1991;1565-1574.
24. Neuhaus KL, von Essen R, Tebbe U. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation. 90:1994;1638-1642.
25. Fox KA. r-hirudin in unstable angina pectoris. Rationale and preliminary data from the Apt pilot study. Eur Heart J. 16:1995;28-32.
26. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 94:1996;911-921.
27. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:1990;385-391.
28. Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinolysis. 5:1994;879-887.
29. Catella-Lawson F. Direct thrombin inhibitors in cardiovascular disease. Coron Artery Dis. 8:1997;105-111.
30. Granger CB, Hirsch J, Califf RM. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 93:1996;870-878.
31. Uriuda Y, Wang QD, Grip L, Rydén L, Sjoquist PO, Mattsson C. Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis. Cardiovasc Res. 32:1996;320-327.
32. Circulation. 90:1994;1631-1637.
33. Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 90:1994;1624-1630.
34. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost. 22:1996;197-202.
35. Pötzsch B, Hund S, Madlener K, Unkrig C, Muller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res. 86:1997;373-383.